Drugs / MT-125
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07604285 | Jul 2026 → Mar 2027 expected | glioblastoma | Myosin Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07185880 | Apr → Oct 2026 expected | glioblastoma | Myosin Therapeutics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-10-22 | Myosin Therapeutics Inc. | Regulatory Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma myosintherapeutics.com ↗
Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular motor proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for the treatment of glioblastoma (GBM). |
| 2025-07-07 | Myosin Therapeutics Inc. | Results Myosin Therapeutics Publishes Two Foundational Studies in the Journal Cell Highlighting a Novel Approach to Treating Cancer and Brain Disorders myosintherapeutics.com ↗
The potential of MT-125 in glioblastoma (GBM) is detailed in the second Cell article , “MT-125 Inhibits Non-Muscle Myosin IIA and IIB and Prolongs Survival in Glioblastoma.” |
| 2025-06-09 | Myosin Therapeutics Inc. | Regulatory Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma myosintherapeutics.com ↗ |
| 2024-02-21 | Myosin Therapeutics Inc. | Regulatory Today, Myosin Therapeutics Announces FDA Orphan Drug Designation for MT-125 for the Treatment of Malignant Gliomas myosintherapeutics.com ↗
Today, Myosin Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for MT-125 for the treatment of malignant gliomas, including glioblastoma (GBM), the most common and lethal glioma. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07185880 ↗ |
| Action | Inhibit | “simultaneous inhibition of NMIIA and IIB with MT-125” NCT07185880 ↗ |
| Modality | Small molecule | “dual small molecule inhibitor” NCT07185880 ↗ |